Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab for MRD in B-ALL Post-HSCT
NCT04044560Phase 2Terminated
- Sponsor
- University of British Columbia
- Start
- Sep 2020
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of blinatumomab in B cell acute lymphoblastic leukemia (B-ALL), sponsored by University of British Columbia. Started Sep 2020; status: terminated.
02
Drugs
blinatumomab
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT04044560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04044560.